RADFORSK is an early stage evergreen fund dedicated to oncology. RADFORSK was founded as an independent foundation in 1986, and was then titled The Norwegian Radium Hospital Research Foundation. RADFORSK invest in oncology, novel therapeutics and diagnostics, with a key focus on immuno-oncology. Our portfolio currently holds 13 companies. RADFORSK has been involved in nine IPOs.
RADFORSK has so far generated MNOK 600 in fund assets and channelled MNOK 200 to cancer research.